Q-omics provides the consensus-scored SRL profile across patient tissues and cancer cell-line models. SRL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SRL is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SRL RNA expression shows 18,394 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, BLCA, and HNSC as cancer lineages where SRL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRL survival associations across molecular data types. SRL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRL RNA expression–survival associations across cancer types. High SRL expression shows unfavorable associations in ACC, but favorable associations in KIRC, LIHC, BRCA, THCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SRL RNA expression.
This table summarizes SRL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SRL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRL shows lower tumor expression in BLCA, KIRC, KICH, LUAD, COAD and LUSC. The BLCA box plot shows higher SRL RNA expression in normal versus tumor tissue (log2 FC = −1.730, t-test p < 0.001).
This table shows molecular features associated with SRL in patient tissues and cancer cell lines. In patient samples, SRL shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SRL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
